Head-To-Head Comparison: enGene (ENGN) & Its Competitors

enGene (NASDAQ:ENGN) is one of 440 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare enGene to similar businesses based on the strength of its profitability, earnings, dividends, institutional ownership, valuation, analyst recommendations and risk.

Profitability

This table compares enGene and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-63.25%	-5.65%
enGene Competitors	-11,893.41%	-127.11%	-24.51%

Earnings and Valuation

This table compares enGene and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
enGene	N/A	$104.74 million	-3.75
enGene Competitors	$154.98 million	-$17.44 million	-74.83

enGene’s competitors have higher revenue, but lower earnings than enGene. enGene is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

64.2% of enGene shares are held by institutional investors. Comparatively, 30.6% of shares of all “Biotechnology” companies are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 22.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

enGene has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500. Comparatively, enGene’s competitors have a beta of 1.21, suggesting that their average stock price is 21% more volatile than the S&P 500.

Dividends

enGene pays an annual dividend of $1.58 per share and has a dividend yield of 25.9%. enGene pays out -97.0% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 3.1% and pay out 3,700.3% of their earnings in the form of a dividend. enGene is clearly a better dividend stock than its competitors, given its higher yield and lower payout ratio.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for enGene and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	6	0	3.00
enGene Competitors	733	2348	5547	66	2.57

enGene currently has a consensus target price of $34.40, indicating a potential upside of 463.01%. As a group, “Biotechnology” companies have a potential upside of 22.23%. Given enGene’s stronger consensus rating and higher possible upside, research analysts plainly believe enGene is more favorable than its competitors.

Summary

enGene beats its competitors on 11 of the 15 factors compared.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.